Time as an outcome measure in fertility-related clinical studies: long-awaited.

clinical trial design endpoints medically assisted reproduction outcomes statistical study design study design time time to live birth trial design

Journal

Human reproduction (Oxford, England)
ISSN: 1460-2350
Titre abrégé: Hum Reprod
Pays: England
ID NLM: 8701199

Informations de publication

Date de publication:
01 08 2020
Historique:
received: 30 10 2019
revised: 27 04 2020
pubmed: 10 7 2020
medline: 28 4 2021
entrez: 10 7 2020
Statut: ppublish

Résumé

Time taken to achieve a live birth is an important consideration that is central to managing patient expectations during infertility treatment. However, time-related endpoints are not reported as standard in the majority of fertility-related clinical studies and there is no internationally recognized consensus definition for such endpoints. There is, therefore, a need for meaningful discussions around the selection of appropriate time-related treatment outcome measures for studies evaluating fertility treatments that will be relevant to diverse stakeholders (e.g. patients, healthcare professionals, clinical scientists, authorities and industry). Here, we provide a proposal for the evaluation of time-related outcome measures in fertility-related clinical studies, alongside associated definitions.

Identifiants

pubmed: 32644107
pii: 5869372
doi: 10.1093/humrep/deaa138
pmc: PMC7398622
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1732-1739

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.

Références

Hum Reprod Update. 2014 Jul-Aug;20(4):530-41
pubmed: 24664156
Fertil Steril. 2018 Jun;109(6):968-979
pubmed: 29935655
Hum Reprod Open. 2018 Jun 15;2018(3):hoy007
pubmed: 30895248
Hum Reprod. 2017 May 1;32(5):999-1008
pubmed: 28204519
BMJ. 2018 Dec 10;363:k4245
pubmed: 30530757
JAMA. 2015 Dec 22-29;314(24):2654-2662
pubmed: 26717030
Popul Dev Rev. 2010;36(2):211-51
pubmed: 20734551
Cochrane Database Syst Rev. 2019 Sep 05;9:CD012692
pubmed: 31486548
Hum Reprod. 2015 Dec;30(12):2703-7
pubmed: 26466912
Hum Reprod. 2019 Apr 1;34(4):659-665
pubmed: 30838395
Hum Reprod. 2016 Dec;31(12):2714-2722
pubmed: 27664214
Hum Reprod Update. 2012 Nov-Dec;18(6):652-69
pubmed: 22869759
J Urol. 2017 Jul;198(1):195-201
pubmed: 28153511
Fertil Steril. 2013 Jun;99(7):2025-30
pubmed: 23454007
Fertil Steril. 2014 Mar;101(3):633-4
pubmed: 24559617
Int J Gynaecol Obstet. 2017 Jul;138(1):42-46
pubmed: 28319264
Fertil Steril. 2017 Sep;108(3):393-406
pubmed: 28760517
Epidemiology. 2010 Jan;21(1):13-5
pubmed: 20010207
JBRA Assist Reprod. 2017 Sep 1;21(3):240-246
pubmed: 28837034
N Engl J Med. 2015 Sep 24;373(13):1230-40
pubmed: 26398071
Hum Reprod Update. 2011 Nov-Dec;17(6):848-60
pubmed: 21652599
Hum Reprod. 2005 May;20(5):1135-43
pubmed: 15790603
Rev Urol. 2011;13(4):e184-90
pubmed: 22232567
Arch Gynecol Obstet. 2003 Jun;268(2):78-81
pubmed: 12768293
Fertil Steril. 2018 Dec;110(7):1227-1230
pubmed: 30503110
J Am Board Fam Med. 2017 Mar-Apr;30(2):230-238
pubmed: 28379830
J Assist Reprod Genet. 2007 Dec;24(12):639-44
pubmed: 18064561
Fertil Steril. 2016 Jan;105(1):129-33
pubmed: 26493118
Fertil Steril. 2016 Jun;105(6):1584-1588.e1
pubmed: 26953733
Am J Obstet Gynecol. 2017 Nov;217(5):566.e1-566.e6
pubmed: 28784418
Cochrane Database Syst Rev. 2018 Feb 01;2:CD012693
pubmed: 29388198
Med J Aust. 2017 Aug 7;207(3):114-118
pubmed: 28764619
Hum Reprod Update. 2005 May-Jun;11(3):261-76
pubmed: 15831503
J Eval Clin Pract. 2011 Aug;17(4):565-74
pubmed: 20698918
Fertil Steril. 2019 Jun;111(6):1036-1046
pubmed: 31155113
Health Policy. 2015 Feb;119(2):174-9
pubmed: 25445061

Auteurs

Sesh K Sunkara (SK)

Division of Women's Health, Faculty of Life Sciences and Medicine, King's College London, London, UK.

Wenjing Zheng (W)

Global Medical Affairs Fertility, Research and Development, Merck KGaA, Darmstadt, Germany.

Thomas D'Hooghe (T)

Global Medical Affairs Fertility, Research and Development, Merck KGaA, Darmstadt, Germany.
Research Group Reproductive Medicine, Department of Development and Regeneration, Organ Systems, Group Biomedical Sciences, KU Leuven (University of Leuven), Leuven, Belgium.
Department of Obstetrics and Gynecology, Yale University, New Haven, CT, USA.

Salvatore Longobardi (S)

Global Clinical Development, Merck Serono S.p.A, Rome, Italy, an affiliate of Merck KGaA, Darmstadt, Germany.

Jacky Boivin (J)

School of Psychology, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH